Patents Assigned to Inserm
  • MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT
    Publication number: 20120015387
    Abstract: An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa.
    Type: Application
    Filed: October 8, 2009
    Publication date: January 19, 2012
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE LILLE
    Inventors: Nathalie De Freitas Caires, Philippe Lassalle, Philippe Hauw
  • Method for predicting the outcome of a critically ill patient
    Patent number: 8097424
    Abstract: The present invention relates to a method for predicting the outcome of a critically ill patient, said method comprising measuring the concentration of Chromogranin A or a fragment thereof in a biological sample obtained from said patient.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: January 17, 2012
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Francis Schneider, Marie-Helene Metz
  • Targeting the histone code as a bacterial strategy for selectively modulating gene expression
    Patent number: 8092989
    Abstract: The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain of Shigella flexneri containing an inactivated ospF gene is also provided.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: January 10, 2012
    Assignees: Institut Pasteur, Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Laurence Arbibe, Philippe Sansonetti, Claude Parsot, Kim Dong Wook, Armelle Phalipon
  • ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2
    Publication number: 20120003224
    Abstract: The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.
    Type: Application
    Filed: July 1, 2011
    Publication date: January 5, 2012
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Armand Bensussan, Laurence Boumsell, Philipe Le Bouteiller
  • Human blood brain barrier model
    Patent number: 8084254
    Abstract: The present invention relates to an immortalized human brain endothelial cell line that is useful as an in vitro model of the blood brain barrier.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: December 27, 2011
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Cornell Research Foundation, Inc.
    Inventors: Pierre-Olivier Couraud, Ignacio Romero, Babette Weksler
  • Method for the in vitro screening of anti-cancer compounds that inhibits SK3 activity, and said anti-cancer compounds
    Patent number: 8084196
    Abstract: The present invention relates to methods for the in vitro screening of an anti-metastatic compound that inhibits activity, methods for determining in vitro the presence or absence of a metastatic cancer in a subject by quantifying SK3 activity, methods for the in vitro assessment of the progression of the metastatic property of a cancer by quantifying SK3.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: December 27, 2011
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Marie Potier, Christophe Vandier, Virginie Joulin
  • Method of treating insulin resistance with a selective inhibitor of CB2 receptor activity
    Patent number: 8084422
    Abstract: The invention relates to the use of a selective inhibitor of CB2 receptor expression and/or for the manufacture of a medicament indented for the treatment and/or the prevention of obesity and obesity-related disorders.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 27, 2011
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Vanessa Deveaux, Fatima Teixeira Clerc, Sylvie Manin, Sophie Lotersztajn, Ariane Mallat, Jeanne Tran-Van-Nhieu
  • Recombinant Monovalent Antibodies
    Publication number: 20110313135
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Application
    Filed: January 13, 2010
    Publication date: December 22, 2011
    Applicants: INSTITUT NATIONAL DE LA SANTE ED DE LA RECHERCHE MEDICALE (INSERM), EFFIMUNE
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells
    Publication number: 20110311544
    Abstract: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.
    Type: Application
    Filed: June 14, 2006
    Publication date: December 22, 2011
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Laurence Boumsell, Jean Kadouche, Armand Bensussan
  • Method of Prognosis and/or Diagnosing an IRS in a Patient Infected with M. Tuberculosis and Optionally HIV
    Publication number: 20110311992
    Abstract: The invention relates to a method of prognosing and/or diagnosing a M. tuberculosis-Immune restoration syndrome (TB-IRS) in an individual infected with M. tuberculosis and optionally HIV comprising comparing the percentage or concentration of ??+ or ??+V?2+T-lymphocytes which express an inhibitory KIR receptor with a predetermined value.
    Type: Application
    Filed: February 5, 2010
    Publication date: December 22, 2011
    Applicant: Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventor: Brigitte Autran
  • DNA AND PROTEINS OR PEPTIDES SPECIFIC OF BACTERIA OF THE NEISSERIA MENINGITIDIS SPECIES, METHODS FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS THEREOF
    Publication number: 20110313026
    Abstract: The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in Neisseria meningitidis, but not in Neisseria gonorrhoeae, or in Neisseria lactamica except the genes involved in the biosynthesis of the polysaccharide capsule, frp A, frp C, opc, por A, rotamase the sequence IC1106, IgA protease, pilline, pilC, transferrin binding proteins and opacity proteins. The invention also concerns the polypeptides corresponding to these DNA and the antibodies directed against these polypeptides. It is applicable in the prevention and the detection of meningococcus induced infections and meningitis.
    Type: Application
    Filed: January 20, 2011
    Publication date: December 22, 2011
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Xavier NASSIF, Colin Tinsley
  • Peptide compositions and their use against the hepatitis C virus
    Patent number: 8080525
    Abstract: Novel peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: December 20, 2011
    Assignees: Transgene SA, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Anne Fournillier, Nourredine Himoudi, Genevieve Inchauspe
  • Methods for Treatment, the Prognostic Assessment and the Detection of Breast Cancer
    Publication number: 20110305633
    Abstract: The present invention relates to methods for the treatment, the prognostic assessment and the detection of breast cancer.
    Type: Application
    Filed: January 5, 2010
    Publication date: December 15, 2011
    Applicant: INSERM(Institut National de la Sante et de la Recherche Medicale)
    Inventors: Patricia Forgez, Anne Gompel
  • Method for obtaining antigen-specific Tr1 regulatory lymphocytes
    Patent number: 8076133
    Abstract: The invention relates to a method for preparing antigen-specific Tr1 regulatory lymphocytes. The inventive method involves the use of artificial antigen-presenting cells expressing a molecule from the HLA class II system and a human LFA-3 molecule and expressing none of the B7-1, B7-2, B7-H1, CD40, CD23, or ICAM-1 costimulatory molecules.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: December 13, 2011
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Hervé Groux, Françoise Cottrez, Abdelilah Wakkach
  • ULTRASOUND DEVICE COMPRISING MEANS TO GENERATE ULTRASOUND BEAM PRESENTING A CONCAVE SEGMENT SHAPE HAVING A SINGLE CURVATURE
    Publication number: 20110301469
    Abstract: A device for treatment of an ocular pathology characterized in that it comprises at least one eye ring (1) wherein the proximal end of said eye ring (1) is suitable to he applied onto the globe and means (2,17) to generate ultrasound beam fixed on the distal end of the eye ring (1), said means to generate ultrasound beam presenting a concave segment shape conformed along a single curvature corresponding to a single direction wherein the concavity is designed to be tuned towards the eyeglobe.
    Type: Application
    Filed: August 18, 2009
    Publication date: December 8, 2011
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), EYE TECH CARE
    Inventors: Fabrizio Romano, Cyril Lafon, Jean-Yves Chapelon, Francoise Chavrier, Alain Birer, Laurent Farcy, Philippe Chapuis
  • Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma
    Publication number: 20110300161
    Abstract: The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.
    Type: Application
    Filed: December 14, 2009
    Publication date: December 8, 2011
    Applicant: INSERM (Institut National de la Sante et de Reche Medicale)
    Inventors: Patricia Forgez, Marco Alifano
  • Use of anti-CD100 antibodies for the treatment of inflammatory disorders affecting the central or peripheral nervous system
    Patent number: 8067247
    Abstract: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: November 29, 2011
    Assignee: Institut National de la Sante Et de la Recherche Medicale (INSERM)
    Inventors: Marie-Françoise Belin, Pascale Giraudon, Laurence Boumsell, Armand Bensussan
  • Nucleic acid compositions and their use against the hepatitic C virus
    Patent number: 8067228
    Abstract: Peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N° 1, a peptide B having at least the amino acid sequence of SEQ ID N° 45, a peptide C having at least the amino acid sequence of SEQ ID N° 127, and a peptide D having at least the amino acid sequence of SEQ ID N° 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: November 29, 2011
    Assignees: Transgene SA, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Anne Fournillier, Nourredine Himoudi, Genevieve Inchauspe
  • HUMAN SOLUBLE CD146, PREPARATION AND USES THEREOF
    Publication number: 20110286963
    Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
    Type: Application
    Filed: January 29, 2010
    Publication date: November 24, 2011
    Applicants: Institut National De La Sante Et De La Recherche Medicale (Inserm), Universite De La Mediterranee
    Inventors: Marcel Blot-Chabaud, Karim Harhouri, Nathalie Bardin, Benjamin Guillet, Françoise Dignat-George
  • AMINOALKYLSTEROL COMPOUNDS WITH ANTITUMORAL AND NEUROPROTECTIVE ACTIVITY
    Publication number: 20110275604
    Abstract: Sterol derivatives of formula (I) and a method for the production of the compounds, a medicament using one of the compounds and a pharmaceutical composition comprising the medicament.
    Type: Application
    Filed: April 1, 2011
    Publication date: November 10, 2011
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Marc POIROT, Philippe De Medina, Sandrine Poirot